Guard Therapeutics International

Guard Therapeutics International AB is a Stockholm-based biopharmaceutical company focused on developing therapies for kidney-related diseases. The company operates as a public Swedish research and development organization centered on drug discovery, clinical development, and partnering for its pipeline assets.

— Guard Therapeutics International
%
Drug development programs100% Therapeutic candidates and research programs aimed at kidney-related diseases.

Guard Therapeutics does not sell mass-market products; its economic counterparties are typically pharmaceutical...

  • Pharmaceutical licensing partnersprimary

    Companies that may license or co-develop Guard Therapeutics' pipeline assets for kidney disease.

  • Research and clinical collaboratorssecondary

    Universities, CROs, and specialist vendors that support discovery and trial execution.

  • Future commercialization partnerssecondary

    Potential downstream partners that would market approved therapies after development.

The company is headquartered in Stockholm, Sweden, and its operations are organized from that base...

  • •Headquartered in Stockholm, Sweden
  • •Operations centered on Swedish corporate and R&D activities
  • •Clinical and partnering footprint may extend beyond Sweden
  • •No disclosed country-level revenue concentration in the provided reports

Guard Therapeutics' strategy is to advance its kidney-disease pipeline through research, clinical development, and...

01
Advance pipeline assetsmedium-term

Clinical and preclinical progress is the main driver of value in a development-stage biotech.

02
Secure collaboration and partnering opportunitiesshort-term

External partners can provide capital, expertise, and commercialization reach.

The company faces the typical risks of development-stage biotech, where clinical outcomes, regulatory decisions, and...

critical

Clinical development failure

Drug candidates may not show sufficient efficacy or safety in trials.

Scope
Pipeline value and future partnering potential
Materiality
high
high

Financing and dilution risk

A pre-revenue biotech typically relies on external capital to fund R&D.

Scope
Operating runway and shareholder dilution
Materiality
high
high

Regulatory approval risk

Authorities may require additional data or reject applications.

Scope
Time to market and commercialization prospects
Materiality
high
medium

Partner dependence

Licensing and collaboration terms can determine access to resources and market reach.

Scope
Development funding and downstream monetization
Materiality
medium
Research and development expense recognition
Operating result and cash burn
Revenue recognition for collaborations or licenses
Timing of reported revenue
Share-based compensation
Personnel cost and EPS

UNITED GUARDIAN INC

UG · Perfumes, Cosmetics & Other Toilet Preparations

InspireMD, Inc.

NSPR · Surgical & Medical Instruments & Apparatus

Guardian Pharmacy Services, Inc.

GRDN · Retail-Drug Stores and Proprietary Stores

Biofrontera Inc.

BFRI · Pharmaceutical Preparations

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

Guardant Health, Inc.

GH · Services-Medical Laboratories

: 11/08/2026